2018 Chabner Colloquium

Session 1:
Novel Targets and Biomarkers

(Overview) Beyond PARP1: Ribosylation as a Target for Cancer Therapy
Victoria Richon, PhD
Ribon Therapeutics

Full Lecture: Audio|Slides

 

(Overview) Melanoma: Clues to Improved Therapeutic Efficacy from Disease Pathogenesis
David E. Fisher, MD, PhD
Massachusetts General Hospital

(Overview) Targeting Cell Death Pathways with Precision Using Functional Assays
Anthony Letai, MD, PhD
Dana-Farber Cancer Institute

Full Lecture: Audio|Slides

 

Session 2:
Enhanced Technology for Early Detection of Cancer

(Overview) Microfluidics for the Characterization of Tumor-specific Extracellular Vesicles
Shannon Stott, PhD
Massachusetts General Hospital

Full Lecture: Audio|Slides

 

(Overview) Clinical Application of Liquid Biopsies and Genotypedirected Targeted Therapies for Metastatic Breast Cancer
Aditya Bardia, MD, MPH
Massachusetts General Hospital

Full Lecture: Audio|Slides

 


Digital RNA-based Analysis of Circulating Tumor Cells for Noninvasive Monitoring of Cancer
Daniel Haber, MD, PhD
Massachusetts General Hospital

Full Lecture: Audio|Slides

 

Session 3:
Progress in Immunotherapy

(Overview) CAR-T Cell Therapy of Ovarian Cancer
Oladapo Yeku, MD, PhD
Massachusetts General Hospital

Full Lecture: Audio|Slides

 

(Overview) Molecular Tumor Board: Resistance to Checkpoint Inhibitors Part 1
David Liu, MD, MPH
Massachusetts General Hospital

(Overview) Molecular Tumor Board: Resistance to Checkpoint Inhibitors Part 2
Ryan Sullivan, MD
Massachusetts General Hospital

Full Lecture: Part 1|Part 2|Slides

 

Session 4:
Junior Faculty Forum


(Overview) The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
Laura M. Spring, MD
Massachusetts General Hospital
Full Lecture: Audio|Slides

 

(Overview) Clinical Utility of Longitudinal Molecular Profiling for Management of ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack, MD
Massachusetts General Hospital

Full Lecture: Audio|Slides

 

(Overview) New Biomarkers in a Novel Antibody-drug Conjugate for Triple Negative Breast Cancer
Aiko Nagayama, MD, PhD
Massachusetts General Hospital

Full Lecture: Audio|Slides

 

(Overview) Lin28B, a Promoter of Metastasis and Drug Resistance
Joseph Franses, MD, PhD
Massachusetts General Hospital

Full Lecture: Audio|Slides

 

2018 Acknowledgments

The Society for Translational Oncology gratefully acknowledges support of this activity from:

Amgen, Inc. Celgene EMD Serono, Inc. Janssen R&D, LLC Novartis Pharmaceuticals Corp.

 


Privacy Policy | Terms of Use | Contact Us

Society for Translational Oncology (STO) is a 501(c)(3) not-for-profit organization.